UK production facility to produce new ‘protein samples’ for fishfeeds
Calysta, the company developing and introducing a new protein source based on single-cell organisms - a bacterium called methylococcus – and destined for inclusion in fishfeeds, has built a ‘market introduction facility’ in Teesside, England, with production beginning in this last quarter of 2016.
At an opening ceremony prior to the start of Aquaculture Europe 2016 being held in Edinburgh in the same week in September, the company said this facility will enable it to provide commercially-representative samples to customers for testing from early 2017.
Additionally, Calysta will be pursuing feed trials in warm water aquaculture species and product registration in jurisdictions outside the European Union.
The company also announced earlier this year a partnership with Cargill Corn Milling with an investment estimated at US$30 million, for production of the FeedKind Aqua protein in North America and marketing worldwide.
A world scale plant is expected to open in the United States by 2018. Cargill’s involvement dramatically accelerates the introduction of commercial production of FeedKind Aqua protein and next generation products are in active development.
FeedKind Aqua protein can be customized to suit customer specifications. Current modifications being pursued include elevating the levels of individual amino acids, incorporating omega-3 fatty acids and optimising the amino acid profile for species-specific dietary requirements.
FeedKind Aqua protein has proven gastrointestinal benefits to salmon, including the prevention of soy-induced enteritis.
The company is also researching potential anti-viral and anti-parasite effects conferred by this new protein product.
Read the full article HERE.
Calysta, the company developing and introducing a new protein source based on single-cell organisms - a bacterium called methylococcus – and destined for inclusion in fishfeeds, has built a ‘market introduction facility’ in Teesside, England, with production beginning in this last quarter of 2016.
 |
| www.calysta.com |
At an opening ceremony prior to the start of Aquaculture Europe 2016 being held in Edinburgh in the same week in September, the company said this facility will enable it to provide commercially-representative samples to customers for testing from early 2017.
Additionally, Calysta will be pursuing feed trials in warm water aquaculture species and product registration in jurisdictions outside the European Union.
The company also announced earlier this year a partnership with Cargill Corn Milling with an investment estimated at US$30 million, for production of the FeedKind Aqua protein in North America and marketing worldwide.
A world scale plant is expected to open in the United States by 2018. Cargill’s involvement dramatically accelerates the introduction of commercial production of FeedKind Aqua protein and next generation products are in active development.
FeedKind Aqua protein can be customized to suit customer specifications. Current modifications being pursued include elevating the levels of individual amino acids, incorporating omega-3 fatty acids and optimising the amino acid profile for species-specific dietary requirements.
FeedKind Aqua protein has proven gastrointestinal benefits to salmon, including the prevention of soy-induced enteritis.
The company is also researching potential anti-viral and anti-parasite effects conferred by this new protein product.
Read the full article HERE.
The Aquaculturists
This blog is maintained by The Aquaculturists staff and is supported by the
magazine International Aquafeed which is published by Perendale Publishers Ltd
For additional daily news from aquaculture around the world: aquaculture-news